Characterization of the clinical and immunologic phenotype and management of 157 individuals with 56 distinct heterozygous NFKB1 mutationsÀngela Deyà‐Martínez, Alla Bulashevska, Nadezhda Camacho-Ordóñez et al.|Journal of Allergy and Clinical Immunology|2020Cited by 127
Unbiased assessment of genome integrity and purging of adverse outcomes at the target locus upon editing of <scp> CD4 <sup>+</sup> </scp> T‐cells for the treatment of Hyper <scp>IgM1</scp>Daniele Canarutto, Luigi Naldini, Claudia Asperti et al.|The EMBO Journal|2023Cited by 10
Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization studyPauline M. Ellerbroek, Leman Yel, Leif G. Hanitsch et al.|Immunotherapy|2024Cited by 5